It has been reported that GAB2 signaling protects CML cells from TKI inhibitor-induced cell death while GAB2 knockdown increases TKI sensitivity [12]. The gene discussed is GAB2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.